Catharine C. Bulik

1.2k total citations
26 papers, 1.0k citations indexed

About

Catharine C. Bulik is a scholar working on Pharmacology, Molecular Medicine and Epidemiology. According to data from OpenAlex, Catharine C. Bulik has authored 26 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pharmacology, 17 papers in Molecular Medicine and 13 papers in Epidemiology. Recurrent topics in Catharine C. Bulik's work include Antibiotics Pharmacokinetics and Efficacy (22 papers), Antibiotic Resistance in Bacteria (17 papers) and Pneumonia and Respiratory Infections (11 papers). Catharine C. Bulik is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (22 papers), Antibiotic Resistance in Bacteria (17 papers) and Pneumonia and Respiratory Infections (11 papers). Catharine C. Bulik collaborates with scholars based in United States, United Kingdom and Australia. Catharine C. Bulik's co-authors include David P. Nicolau, Joseph L. Kuti, Jared L. Crandon, Paul G. Ambrose, Sujata M. Bhavnani, Alan Forrest, Christina Sutherland, Ólanrewaju O. Okusanya, Henry Christensen and Brian VanScoy and has published in prestigious journals such as Clinical Cancer Research, Journal of Clinical Microbiology and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Catharine C. Bulik

26 papers receiving 997 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catharine C. Bulik United States	18	739	736	415	255	140	26	1.0k
Francesca Ginocchio Italy	10	446 0.6×	789 1.1×	320 0.8×	257 1.0×	210 1.5×	14	1.1k
Jovan Jacob Australia	9	923 1.2×	1.1k 1.5×	558 1.3×	178 0.7×	61 0.4×	9	1.3k
Christina Sutherland United States	21	712 1.0×	577 0.8×	373 0.9×	207 0.8×	227 1.6×	45	1.1k
Kimberly R. Ledesma United States	18	614 0.8×	734 1.0×	291 0.7×	170 0.7×	53 0.4×	29	956
Olga Lomovskaya United States	11	571 0.8×	777 1.1×	282 0.7×	218 0.9×	83 0.6×	16	895
C Andrew DeRyke United States	17	639 0.9×	636 0.9×	401 1.0×	338 1.3×	194 1.4×	60	1.1k
Michael A. Zhanel Canada	9	389 0.5×	610 0.8×	275 0.7×	183 0.7×	74 0.5×	10	877
Mari Ariyasu Japan	11	873 1.2×	1.2k 1.6×	428 1.0×	561 2.2×	131 0.9×	26	1.5k
Athina Argyrοpoulou Greece	9	325 0.4×	508 0.7×	248 0.6×	212 0.8×	128 0.9×	15	725
Jocelyn Qi-Min Teo Singapore	19	335 0.5×	523 0.7×	244 0.6×	275 1.1×	133 0.9×	51	886

Countries citing papers authored by Catharine C. Bulik

Since Specialization

Citations

This map shows the geographic impact of Catharine C. Bulik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catharine C. Bulik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catharine C. Bulik more than expected).

Fields of papers citing papers by Catharine C. Bulik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catharine C. Bulik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catharine C. Bulik. The network helps show where Catharine C. Bulik may publish in the future.

Co-authorship network of co-authors of Catharine C. Bulik

This figure shows the co-authorship network connecting the top 25 collaborators of Catharine C. Bulik. A scholar is included among the top collaborators of Catharine C. Bulik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catharine C. Bulik. Catharine C. Bulik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maguire, William F., Daniel Lee, Chana Weinstock, et al.. (2024). FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(10). 2011–2016. 13 indexed citations

Bhavnani, Sujata M., Jeffrey Hammel, Elizabeth A. Lakota, et al.. (2023). Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae. Antimicrobial Agents and Chemotherapy. 67(4). e0221321–e0221321. 12 indexed citations

Owens, Robert C., Catharine C. Bulik, & David R. Andes. (2018). Pharmacokinetics–pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder. Diagnostic Microbiology and Infectious Disease. 91(4). 371–382. 7 indexed citations

Bulik, Catharine C., Justin Bader, Li Zhang, et al.. (2017). PK–PD Compass: bringing infectious diseases pharmacometrics to the patient’s bedside. Journal of Pharmacokinetics and Pharmacodynamics. 44(2). 161–177. 11 indexed citations

Nicasio, Anthony M., Brian VanScoy, Rodrigo E. Mendes, et al.. (2016). Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model. Antimicrobial Agents and Chemotherapy. 60(4). 2075–2080. 46 indexed citations

Bulik, Catharine C., Ólanrewaju O. Okusanya, Elizabeth A. Lakota, et al.. (2016). Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models. Antimicrobial Agents and Chemotherapy. 61(2). 28 indexed citations

Okusanya, Ólanrewaju O., Sujata M. Bhavnani, Jeffrey Hammel, et al.. (2014). Evaluation of the Pharmacokinetics and Pharmacodynamics of Liposomal Amikacin for Inhalation in Cystic Fibrosis Patients with Chronic Pseudomonal Infections Using Data from Two Phase 2 Clinical Studies. Antimicrobial Agents and Chemotherapy. 58(9). 5005–5015. 21 indexed citations

Kamal, Mohamed, Scott A. Van Wart, Craig R. Rayner, et al.. (2013). Population Pharmacokinetics of Oseltamivir: Pediatrics through Geriatrics. Antimicrobial Agents and Chemotherapy. 57(8). 3470–3477. 20 indexed citations

VanScoy, Brian, Rodrigo E. Mendes, Jennifer McCauley, et al.. (2013). Pharmacological Basis of β-Lactamase Inhibitor Therapeutics: Tazobactam in Combination with Ceftolozane. Antimicrobial Agents and Chemotherapy. 57(12). 5924–5930. 62 indexed citations

10.

Okusanya, Ólanrewaju O., Brian T. Tsuji, Jürgen B. Bulitta, et al.. (2011). Evaluation of the pharmacokinetics–pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. Diagnostic Microbiology and Infectious Disease. 70(1). 101–111. 12 indexed citations

11.

Bulik, Catharine C., Pamela R. Tessier, Rebecca A. Keel, Christina Sutherland, & David P. Nicolau. (2011). In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms. Antimicrobial Agents and Chemotherapy. 56(1). 544–549. 50 indexed citations

12.

Bulik, Catharine C. & David P. Nicolau. (2011). Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 55(6). 3002–3004. 165 indexed citations

13.

Koomanachai, Pornpan, Catharine C. Bulik, Joseph L. Kuti, & David P. Nicolau. (2010). Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clinical Therapeutics. 32(4). 766–779. 47 indexed citations

14.

Bulik, Catharine C., Kathy Fauntleroy, Stephen G. Jenkins, et al.. (2010). Comparison of Meropenem MICs and Susceptibilities for Carbapenemase-Producing Klebsiella pneumoniae Isolates by Various Testing Methods. Journal of Clinical Microbiology. 48(7). 2402–2406. 65 indexed citations

15.

Bulik, Catharine C. & David P. Nicolau. (2010). In VivoEfficacy of Simulated Human Dosing Regimens of Prolonged-Infusion Doripenem against Carbapenemase- ProducingKlebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 54(10). 4112–4115. 43 indexed citations

16.

Bulik, Catharine C., Richard Quintiliani, J. Samuel Pope, Joseph L. Kuti, & David P. Nicolau. (2009). Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis – A review of 3 cases. Respiratory Medicine CME. 3(3). 146–149. 13 indexed citations

17.

Crandon, Jared L., Catharine C. Bulik, & David P. Nicolau. (2009). In Vivo Efficacy of 1- and 2-Gram Human Simulated Prolonged Infusions of Doripenem against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 53(10). 4352–4356. 29 indexed citations

18.

Bulik, Catharine C., Jack D. Sobel, & Michael D. Nailor. (2009). Susceptibility profile of vaginal isolates of Candida albicans prior to and following fluconazole introduction - impact of two decades. Mycoses. 54(1). 34–38. 26 indexed citations

19.

Bulik, Catharine C., Henry Christensen, & David P. Nicolau. (2009). In Vitro Potency of CXA-101, a Novel Cephalosporin, against Pseudomonas aeruginosa Displaying Various Resistance Phenotypes, Including Multidrug Resistance. Antimicrobial Agents and Chemotherapy. 54(1). 557–559. 37 indexed citations

20.

Crandon, Jared L., Catharine C. Bulik, Joseph L. Kuti, & David P. Nicolau. (2009). Clinical Pharmacodynamics of Cefepime in Patients Infected with Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 54(3). 1111–1116. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact